IFP Advisors
PLX icon

IFP Advisors’s Protalix BioTherapeutics PLX Stock Holding History

IFP Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-9
Closed -$21 – 5360
2026
Q2 		$21 Buy
9
+6
+200% +$13 ﹤0.01% 5067
2026
Q1 		$7 Buy
+3
New +$7 ﹤0.01% 4981

Other funds holding PLX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

IFP Advisors's PLX Position: Q3 2026 in Review

IFP Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2026, closing a stake of 9 shares — an estimated $21 sold.

IFP Advisors first reported a position in PLX in Q1 2026 and held it in 2 quarters. The position peaked at $21 in Q2 2026. 48 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • IFP Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2026 after selling out during the quarter.
  • IFP Advisors sold 9 Protalix BioTherapeutics shares in Q3 2026, an estimated $21.
  • IFP Advisors first reported a position in Protalix BioTherapeutics in Q1 2026 and held it in 2 quarters.
  • IFP Advisors's Protalix BioTherapeutics position peaked at $21 in Q2 2026.
  • 48 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.